Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pacritinib before reduced-intensity conditioning allogeneic stem cell transplantation in myelofibrosis (phase II)
2015-000195-98Phase 2Terminated
- Sponsor
- HOVON
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pacritinib in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF), sponsored by HOVON. Primary endpoint: Composite transplant failure at day 180 post-transplant. Started Feb 2016; status: terminated.
02
Drugs
pacritinib
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on 2015-000195-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000195-98.